This platform will play an important part of Boehringer Ingelheim’s broader strategy to capture translational disease insights from large external healthcare biobanks and ultimately to accelerate the development of innovative medicines.

''Omica.bio and Lifebit share a common commitment to never let the lack of data stand in the way of scientific progress. This partnership presents an exciting opportunity to bring the genetic diversity of Latin American populations to the global research agenda. This has the potential to transform global research endeavours whilst also directly benefiting people in Latin America.”